THE United States and Zambia have signed the Tuberculosis Accelerator Statement of Partnership to end TB in Zambia.
The Statement of Partnership represents a joint approach to achieve Zambia’s 2022 United Nations High Level Meeting TB targets: 1) treat over 200,000 people with drug-susceptible TB; 2) treat 4,800 people with drug-resistant TB; and 3) put over 400,000 people on TB preventive therapy.
According to a statement, these targets can only be achieved with coordination and cooperation at the highest levels.
It stated that fighting TB was a top priority for the US government.
On September 26, 2018, Mark Green, administrator of USAID, launched a new, worldwide innovative model, “The Global Accelerator to End Tuberculosis,” that leverages additional resources from countries, private sector partners, and other local organisations to meet the UN General Assembly High Level Meeting TB targets.
Since 2000, the US government partnerships have resulted in a nearly 50 per cent reduction in TB-related deaths, and saved more than 54 million lives.
According to the statement, the average global rate of decline in TB incidence is two per cent per year.
It stated that through the Global Accelerator to End TB, the US government together with country counterparts aim to decrease this by four to five per cent per year by 2022.
“Due to the high prevalence of TB and TB/HIV, Zambia is a priority country for the Global TB Accelerator strategy,” said USAID Zambia director Sheryl Stumbras.
“The United States and the Ministry of Health will leverage existing partnerships, better align with local communities, and bring in new partners to deliver performance-based results towards the global target of TB elimination.”
It stated that the United States would continue to work in collaboration with the Ministry of Health’s National TB Programme, local partners, TB grant recipients, and other relevant stakeholders to reach every person with TB, cure those in need of treatment, prevent the spread of disease and new infections, and promote self-reliance in the response to TB.